BIOS — Stock Film
STOCK FILMSCENE 1/9BIOS · $10.80
Stock Expert AI presents
BIOS
BioPlus Acquisition Corp
~3 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
BioPlus Acquisition Corp. A quick introduction.

On the stock market since 2022, it operates in the world of money and finance. Now — the numbers.

on the stock market since 2022
$209.1M market value
Revenue last year:
$0
The net profit left over:
$0
Out of every $100 in sales, less than $1 stays as net profit.

This is an established company with proven profits.

THE SALES TREND
Sales have been shrinking.

An average decline of 100% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.

$935.6M
2016
$817.2M
2017
$708.9M
2018
$0
2021
$0
2022
What executives did with their own stock over the last 12 months:
4 buy2 sell

Executives buying with their own money is usually read as confidence in the company’s future.

THE FIVE-YEAR JOURNEY
Bumpy, but the direction is up.

The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.

1
THE BRIGHT SIDE · 1/1
Executives are buying their own stock

Over the last 12 months, company executives reported 4 buys and 2 sells. Management buying with its own money is usually read as a good sign.

1
THE RISKS · 1/1
The stock has lost its spark

The price action doesn’t yet back an upward turn.

FINALE · THE GRADE
D
0 / 100 · MoonshotScore

On our five-subject report card, BIOS sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: BIOS is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Jul 24, 2026 · stockexpertai.com · Stock Film